cyrilzakka/clinical-trials huggingface dataset:
Teaching First Aid and Trauma Management to School Students

This proposal aims to describe research that will utilize first aid in primary education students and will attempt to identify the frequency with which the training should be repeated and the type of trainer who will carry out the training program.

The training concerns courses with theoretical knowledge and practical skills related to first aid. Taking into account children's cognitive and psychological development, students will be trained in the following topics: calling an ambulance, managing bleeding, handling an unconscious patient, drowning, and managing a head injury. Classroom teachers and specialized staff will teach classes. The evaluation of knowledge and skills will be done with a questionnaire. The evaluation will take place before and immediately after the training, two months and seven months after the training.

Eligibility Criteria:
Inclusion Criteria:

* Students at primary schools and kindergarten, 4-9 years old

Exclusion Criteria:

* Students over 9 years old
Genetic Variants and Iron Absorption

The two specific aims of this study are: 1) to assess the impact of a genetic variant on iron status; 2) to assess the impact of a genetic variant on non-heme absorption among Asian women. The investigators hypothesize that the genetic variant could enhance iron status and iron absorption in Asian women.

To determine the HFE genotype of female Asian study volunteers, we collected venous blood samples and extracted DNA from these blood samples. HFE genotype was determined as CC, CT, and TT and used to assess possible differences in iron status as a function of genotype. To measure the impact of genotype on non-heme Fe absorption, a sub-group of women with the CC (n=10) or TT (n=11) genotype were invited to return for an Fe absorption study. Each volunteer consumed stable 57Fe (as ferrous sulfate). Two weeks after ingesting this tracer, a blood sample was collected from each woman and the amount of non-heme (57Fe) iron incorporated into red blood cells was measured with magnetic sector thermal ionization mass spectrometry. Possible associations between iron status and iron absorption as a function of genotypes were explored. Data from this study will provide information that aims to improve human health by better understanding the iron requirements of individuals with different genetic background.

Eligibility Criteria:
Inclusion Criteria:

* non-pregnant and between the ages of 18\~35 y
* East Asian descent with both maternal and paternal grandparents from East Asia, including China, Japan, South Korea, Vietnam, Thailand, Malaysia and Singapore

Exclusion Criteria:

* taking or planing to take any vitamin or mineral supplements during the study period
* pre-existing medical problems that might impact inflammation or Fe status, including malabsorption, blood disorders, ulcers, joint diseases and asthma
* taking any prescribed medications known to affect iron homeostasis
A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors

The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-7787 injection monotherapy for patients with advanced solid tumors. To explore the reasonable dosage of SHR-7787 injection monotherapy for patients with advanced solid tumors.


Eligibility Criteria:
Inclusion Criteria:

1. Ability to understand and voluntarily agrees to participate by giving written informed consent for the study;
2. Patients with unresectable recurrent or metastatic solid tumors;
3. There is at least one lesion could be measured;
4. An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1;
5. Adequate organ functions as defined;
6. Life expectancy ≥3 months.

Exclusion Criteria:

1. Patients with known active central nervous system (CNS) metastases;
2. Subjects who had other malignancy in five years before the first dose;
3. Patients with tumor-related pain that cannot be controlled as determined;
4. Patients with serious cardiovascular and cerebrovascular diseases;
5. Uncontrollable third-space effusion, such as pleural effusion, pericardial effusion or peritoneal effusion;
6. Patients with Severe infections;
7. History of immunodeficiency;
8. History of autoimmune diseases;
9. Unresolved CTCAE Grade \>1 toxicity attributed to any prior anti-tumor therapy
10. Active infection;
11. Pregnant or nursing women;
12. Known history of serious allergic reactions to the investigational product or its main ingredients.
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

This study will assess the safety, tolerability and efficacy of AQW051 in treating moderate to severe L-dopa induced dyskinesias (movement disorders) in patients with Parkinson's disease.


Eligibility Criteria:
Inclusion Criteria:

* Patients with Parkinson's disease
* Patients with dyskinesias for at least 3 months
* Patients with moderate to severe dyskinesias
* Patients on L-dopa treatment for at least 3 years

Exclusion Criteria:

* Patients with atypical Parkinson's disease
* Patients who have had prior surgery for Parkinson's disease
* Patients who are cognitively impaired, have psychosis, have confusional states or hallucinate
* Patients who received neuroleptics or anti-psychotics within 2 months
* Women of child-bearing potential

Other protocol-defined inclusion/exclusion criteria may apply.
The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM

The study of investigators indicated that TMZ can up-regulate dopamine D2 receptor (DRD2) expression, and mediates Ferroptosis inhibition and chemoresistance of GBM. The clinical data also proved that the DRD2 expression in recurrent GBM is significantly higher than that in primary GBM. Moreover, the DRD2 antagonist haloperidol can attenuate the above function of DRD2, and increase the sensitivity of GBM to the TMZ by inducing fatal autophagy and ferroptosis. In xenograft mice, the combined usage of haloperidol and Temozolomide (TMZ) can significantly inhibit tumor growth and increase overall survival. The investigators' findings have been published in Clinical cancer research. Haloperidol known as a butylbenzene antipsychotic drug, has been widely used in several kinds of mental illnesses, such as depression, schizophrenia, and Bipolar disorder. And the safe dosage of the haloperidol is clear so far. So in this study, the investigators will recruit the patients who suffered from recurrent GBM, and evaluate the effectiveness of single TMZ chemotherapy or combined with haloperidol.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients
* Primary GBM underwent surgery and TMZ chemoradiotherapy, and MRI confirmed the tumor recurrence
* Without severe cardiac diseases

Exclusion Criteria:

* Child patients (\<18 years)
* Recurrence tumors grow fast, which needs surgery removal
* H3K27M midline glioblastoma
* Suffered with severe cardiac diseases
Effects of HBO Therapy on Muscular Insulin Resistence in Type 2 Diabetes

Hyperbaric oxygen therapy (HBO) is applied for several diseases. The effect on insulin sensitivity is yet unknown. Hypothesis: HBO therapy improves insulin sensitivity in patients.

HBO therapy is applied to improve wound healing in diabetic patients with foot ulcera. However, it might induce oxidative stress as well as improve antioxidative capacity. The effects on insulin sensitivity in humans and will be tested in the study.

Eligibility Criteria:
Inclusion Criteria:

* Aged ≥ 30 years- ≤ 70 years
* Balanced sex (50: 50)
* BMI 20- 25 kg/m 2 normal- weight group
* BMI 35- 39,9 kg/m 2 (Obese typ II)

Exclusion Criteria:

* Acute illness 2 weeks before start of examination
* Autoimmune or Immune disorder deseases (Leukozyten \< 5000/µl
* Renal insufficiency (Kreatin \> 1,5 mg/dl)
* Heart disease, condition after heart attack
* Anemia (Hb \<12g/l, contolled before every day of eximination) or blood donations 4weeks before eximinatin.
* Participation in another trial within the last 2 weeks
* Pharmacological- immuno therapy (Cortisol, Antihistaminika, ASS)
* Thyroid disorders
* Glitazone or Insulin- Therapy
* Pragnancy, Lactation, Menstruation
* Smoking cigaretts, Alcohol- and drug abuse
* Psychiatric disorders
* Risk for/ or diagnosed HIV/ AIDS or Hepatitis B/C
* Liver disease, which are not caused by non- alcoholic steato- hepatitis
* Working on night shifts or irregular rhythem of night- day
* Impaired wound healing or clotting disorders
* Allergic reaction to local anesthetics
* Malignant cancer
Patient Characteristics and Treatment Modalities in COPD Patients in China

Chronic obstructive pulmonary disease (COPD) is a complex disease characterized by multiple clinical manifestations as well as co-morbidities. While COPD subjects have traditionally been classified based solely on airflow limitation (forced expiratory volume in one second \[FEV1\]), a new classification system was introduced in the year of 2011 by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) that recommended subjects with COPD should be classified based on a combination of airflow limitation, disease impact (determined by symptom burden and activity limitation) and history of exacerbation. This approach results in the classification of subjects in four groups: A (low risk, less symptoms), B (low risk, more symptoms), C (high risk, less symptoms), and D (high risk, more symptoms). This classification system was further refined in year 2013, specifically around the history of exacerbation definition, where having ≥1 exacerbation leading to hospital admission in preceding year was added as a criteria for classification into the "high risk" C or D groups. Further, in the year 2016, there was a refinement of the disease impact criteria that suggest the use of the COPD Assessment Test (CAT) score (over the Modified British Medical Research Council Dyspnea Scale \[mMRC\] score) as the preferred tool to determine classification as "more symptoms" or "less symptoms". This study aims to understand subject characteristics and current treatment modalities in different groups classified by GOLD 2016 comprehensive classification system and to understand if current treatment choice is concordant with the GOLD recommendations in real life clinical practice in China tertiary hospitals. It will provide a useful point-in-time description of COPD subject characteristics and current treatment modalities in real life clinical practice in China.


Eligibility Criteria:
Inclusion criteria

* Aged 40 years and older
* A clinical diagnosis of COPD for at least one year: dyspnea, chronic cough or sputum production, and a history of exposure to risk factors for the disease and lung function test FEV1/ FVC \<0.7(post bronchodilator)
* Out-patient
* Able to read, comprehend, and record information in Chinese
* A signed and dated written informed consent must be obtained from the subject prior to study participation Exclusion criteria
* Current exacerbation or an exacerbation within the preceding one month
* Other unstable diseases which could influence CAT and lung function results (judged by physicians)
* A medical diagnosis of active tuberculosis, cystic fibrosis, any other pulmonary condition, lung cancer, or hypereosinophilic syndromes (HES)
* Currently participating in another COPD clinical study which provides the subject investigational medication and/or disease management
A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients

This open label, multi-centre phase II study will assess the efficacy and safety of single agent SC10914 in metastatic breast cancer patients with gBRCA 1/2 mutations.


Eligibility Criteria:
Inclusion Criteria:

1. Germline mutation in BRCA1 or BRCA2
2. Histologically or cytologically confirmed breast cancer with evidence of metastatic disease.
3. Prior therapy with an anthracycline and/or a taxane in either an adjuvant or metastatic setting
4. Patients who have received platinum (cisplatin or carboplatin, either as monotherapy or in combination) for advanced breast cancer are eligible to enter the study provided platinum-free interval at least 6 months (time from last dose of platinum chemotherapy to disease progression
5. Patients who have received platinum as potentially curative treatment for a prior cancer (e.g. ovarian cancer) or as adjuvant/neoadjuvant treatment for breast cancer are eligible provided at least 12 months have elapsed between the last dose of platinum-based treatment and eligible .
6. Patients with estrogen and/or progesterone receptor-positive disease must have received and progressed on at least one endocrine therapy (adjuvant or metastatic), or have disease that the treating physician believes to be inappropriate for endocrine therapy .
7. At least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by CT (MRI where CT is contraindicated) and is suitable for repeated assessment as per RECIST 1.1.
8. ECOG performance status 0-1.
9. Adequate bone marrow, kidney and liver function

Exclusion Criteria:

1. Prior treatment with PARP inhibitor.
2. Patients with HER2 positive disease
3. Untreated and/or uncontrolled brain metastases
4. Known HIV (Human Immunodeficiency Virus) infection.
5. Persistent toxicities (≥CTCAE grade 2) caused by previous cancer therapy, excluding alopecia
6. Pregnant or breast feeding women
Prenatal Behavioral Intervention to Prevent Maternal Cytomegalovirus (CMV) in Pregnancy

This study will evaluate whether a brief prenatal clinic-based cytomegalovirus (CMV) risk-reduction behavioral intervention will prevent maternal CMV infections during pregnancy in women.

Pregnant women will be recruited into the study following their first prenatal visit. After enrollment, they will be randomized to either the CMV risk-reduction intervention or an attention-matched control stress-reduction group stratified by their CMV serostatus.

Women in both groups will attend an individualized behavioral skills session, watch a short video, receive a take-home packet, receive weekly text messages for 12 weeks that reinforce the experimental and control health messages, and attend follow-up visits at 6 and 12 weeks. Saliva, urine, vaginal, and blood specimens will be collected at enrollment and 6 and 12 weeks follow-up visits. Additionally, at-home saliva and vaginal specimen collection will occur at 3 and 9 weeks and once during the third trimester of pregnancy. At delivery, a saliva specimen will be collected from both the mother and infant, along with a remnant cord blood specimen.

Eligibility Criteria:
Inclusion Criteria:

* enrollment in prenatal care before 20 weeks gestation
* absence of CMV IgG on serological testing indicating CMV seronegative status or CMV positive (nonprimary) defined as maternal CMV infection pre-dating pregnancy defined by a high IgG avidity index or a positive CMV IgG in the presence of a negative CMV immunoglobulin M (IgM)

Exclusion Criteria:

* known major fetal anomalies or demise
* planned termination of pregnancy
* planned use of immune globulin, ganciclovir, or valganciclovir
* maternal immune impairment (e.g., HIV infection, organ transplant on anti-rejection medications)
* pre-enrollment ultrasound suggestive of established fetal CMV infection or positive fetal CMV results from culture or PCR
* pre-enrollment CMV seroconversion or primary CMV infection in pregnancy
* unable to determine if CMV infection is a nonprimary infection due to intermediate or undefined CMV serological test results
* pre-enrollment blood, ultrasound, or amniotic fluid testing indicating congenital infection with rubella, syphilis, varicella, parvovirus, toxoplasmosis or other congenital infection
* intention of the patient or of the managing obstetricians for the delivery to be outside of the University of Alabama at Birmingham hospital
Early Detection of Barrett's Esophagus Through Deep Image Retrieval

Barrett's oesophagus is a condition in which the area between the oesophagus and stomach no longer closes, allowing acidic contents of the stomach to enter the oesophagus and damage the lining. The project aims to assist clinicians by offering informed biopsy process, in which the system presents the operator with clinical outcomes of patients with visually similar GI tracts. The project goal is to assess the use of artificial intelligence-based similarity detection systems to better inform biopsy placement, increasing the reliability of bi-yearly inspections.

The project intention is to acquire secondary endoscopy captured data from clinicians to create a sufficient dataset to train a learning system to achieve the stated objective. The data required will feature footage (images/videos) from inside the oesophagus. The preferred data would contain associated diagnosis notes and description, however, data without diagnosis can still be used. All data can and will be anonymised, as personal information will not be useful in this work.

The data will be labelled by either researchers, or professional clinicians and prepared ready to feed into a chosen learning AI system. Through an iterative learning process, the chosen AI system will learn to discriminate between severity of Barrett's oesophagus and output optimal biopsy target.

Eligibility Criteria:
Inclusion Criteria:

* Adult
* Attending Southmead Hospital for on OGD
* Has capacity
* Initially any indication, later patients with known Barrett's oesophagus

Exclusion Criteria:

* Children (\<18)
* Patients without capacity
* Urgent and emergency procedures
* Limited English
Incidental Findings in Abdominal Surgery

Despite the recent advancement in diagnostic modalities, many surgeons experience till this day unexpected findings during the course of surgery. Very few information is available in the medical literature in order to assist the surgeon with the anticipation and preparation to deal with Incidental Findings (IFs). Such valuable information can be of great benefit to the surgeon, as the surgical team can prepare himself better -technically and scientifically- to deal with the common expected IFs. The authors aim to examine the incidence of all IFs in abdominal surgery -laparoscopy or laparotomy- and identify possible associations through a cross-sectional designed study conducted in Aleppo University Hospital - Department of Surgery. The authors collected patients' data who underwent abdominal surgery during the period of the two-consecutive years 2018-2019.


Eligibility Criteria:
Inclusion Criteria:

* patients older than 13 y/o
* patients undergoing laparoscopy or laparotomy that must include a proper inspection of the abdominal cavity

Exclusion Criteria:

* patients aged 13 y/o or less
* patients with incomplete data
* gynecological procedures even if it involves laparotomy or laparoscopy.
Second Haplo-transplantation for Graft Failure

Graft failure is a fatal complication following allogeneic stem cell transplantation where a second transplantation is usually required for salvage. There are no recommended regimens for second transplantations for graft failure, especially in the haploidentical transplant setting. We recently reported encouraging outcomes using a novel method (haploidentical transplantation from a different donor after conditioning with fludarabine and cyclophosphamide). However, the study was performed in single-center and with very small sample size. Therefore, it should be further validated via multicenter study. In this multi-center study, we aim to further evaluate the safety and efficacy of this protocol.


Eligibility Criteria:
Inclusion Criteria:

* 1. Primary disease: hematological malignancies (AML, CML, MDS, lymphoma, etc.); 2. Graft failure after the first haploidentical stem cell transplantation; 3. Time from the first transplantation to the second transplantation is less than 180 days; 4. Age≥14 years.

Exclusion Criteria:

* 1. Active infections; 2. Active GVHD; 3. Organ dysfunction: hepatic injury (Tbil≥2ULN), renal injury (Cr≥1.5ULN), heart injury (EF%\<50% or symptomatic heart failure); 4. Eastern Cooperative Oncology Group (ECOG) score\>2; 5. Expected life time\<30 days; 5. Patients could not cooperate; 6. Other situations that are considered inappropriate for enrollment by the investigators,
Retrospective Analysis of a Population of Patients With With Severe Traumatic Head Injury and Woken Early

Observational retrospective study that included all patients meeting the inclusion criteria from 1st January 2014 to 31st December 2015.

The objective of the study is to describe and compare two populations of patients with severe traumatic head injury arriving under sedation in the Department in whom the sedation was not continued.


Eligibility Criteria:
Inclusion Criteria:

- Patients with traumatic head injuring arriving in the Neurosurgery and Traumatologic Intensive Care Unit under sedation

Exclusion Criteria:

* Brain death within the 48h following admission,
* Stroke leading to the traumatic head injury,
* Death within the 24h following admission,
* Patients not under sedation on admission to the unit,
* Non-sedated patients transferred directly to the operating theatre
* Traumatic brain injury in patients presenting chronic sub-dural haematoma,
* Continued sedation (\> 15h) in the ICU.
Quantification of Human Adipogenesis

This pilot study is using a novel technology to measure the rate of turnover of new fat cells. Analysis of volunteer samples is ongoing, however the study is currently not enrolling new volunteers.


Eligibility Criteria:
Inclusion Criteria:

* Aged 18-49 years.
* Healthy.

Exclusion Criteria:

* Significant chronic medical illness.
* Illicit substance or alcohol abuse.
* Body mass index \> 27 kg/meters squared.
* Underweight (BMI \< 20 kg/m2).
* History of keloid formation (excessive scarring).
* Pregnant.